Log in

Moderna Stock Price, News & Analysis (NASDAQ:MRNA)

+0.40 (+2.87 %)
(As of 10/16/2019 01:08 AM ET)
Today's Range
Now: $14.33
50-Day Range
MA: $15.89
52-Week Range
Now: $14.33
Volume1.16 million shs
Average Volume1.56 million shs
Market Capitalization$4.73 billion
P/E RatioN/A
Dividend YieldN/A
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:MRNA



Sales & Book Value

Annual Sales$135.07 million
Book Value$4.65 per share



Market Cap$4.73 billion
Next Earnings Date11/6/2019 (Estimated)

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

Moderna (NASDAQ:MRNA) Frequently Asked Questions

What is Moderna's stock symbol?

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

How were Moderna's earnings last quarter?

Moderna Inc (NASDAQ:MRNA) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The company had revenue of $13.08 million for the quarter, compared to analyst estimates of $18.80 million. View Moderna's Earnings History.

When is Moderna's next earnings date?

Moderna is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Moderna.

What price target have analysts set for MRNA?

9 analysts have issued 1 year price objectives for Moderna's stock. Their predictions range from $20.00 to $40.00. On average, they expect Moderna's share price to reach $27.56 in the next year. This suggests a possible upside of 92.3% from the stock's current price. View Analyst Price Targets for Moderna.

What is the consensus analysts' recommendation for Moderna?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Moderna.

Has Moderna been receiving favorable news coverage?

Press coverage about MRNA stock has trended somewhat negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Moderna earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Moderna.

Are investors shorting Moderna?

Moderna saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 24,030,000 shares, an increase of 60.0% from the August 30th total of 15,020,000 shares. Based on an average daily trading volume, of 2,450,000 shares, the days-to-cover ratio is currently 9.8 days. Currently, 12.5% of the shares of the company are short sold. View Moderna's Current Options Chain.

Who are some of Moderna's key competitors?

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Audentes Therapeutics (BOLD), NVIDIA (NVDA), Spectrum Pharmaceuticals (SPPI), Visa (V), Amarin (AMRN), Dropbox (DBX), eHealth (EHTH) and Global Blood Therapeutics (GBT).

Who are Moderna's key executives?

Moderna's management team includes the folowing people:
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder, Chairman & Member of Technology Advisory Board (Age 56)
  • Mr. Stéphane Bancel, CEO & Director (Age 46)
  • Dr. Stephen Hoge, Pres (Age 43)
  • Dr. Lorence H. Kim, Chief Financial Officer (Age 45)
  • Jennifer Lee, Chief Accounting Officer

When did Moderna IPO?

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

How do I buy shares of Moderna?

Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Moderna's stock price today?

One share of MRNA stock can currently be purchased for approximately $14.33.

How big of a company is Moderna?

Moderna has a market capitalization of $4.73 billion and generates $135.07 million in revenue each year. The company earns $-384,730,000.00 in net income (profit) each year or ($4.95) on an earnings per share basis. Moderna employs 760 workers across the globe.View Additional Information About Moderna.

What is Moderna's official website?

The official website for Moderna is http://www.modernatx.com/.

How can I contact Moderna?

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-6500 or via email at [email protected]

MarketBeat Community Rating for Moderna (NASDAQ MRNA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  76
MarketBeat's community ratings are surveys of what our community members think about Moderna and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel